Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) has provided a corporate update on its barium and iodine contrast media projects, outlining a strategic roadmap to address critical supply chain vulnerabilities in the diagnostic imaging sector. The global contrast media market is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's vertically integrated strategy spans mineral discovery to finished product manufacturing, ensuring supply security and competitive production costs.
The company is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek (FC) barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate, with average purity of 98.8% BaSO4, exceeding pharmaceutical grade (97.5%). Voyageur has completed product development for five Health Canada approved barium products with Alberta Veterinary Laboratories, generating approximately C$32,000 in initial sales. The FC BFS is expected in the second half of 2026, following geotechnical drilling at the quarry site. A preliminary economic assessment valued the FC project at a net present value of $344 million, as reported in a January 11, 2022 news release.
On the regulatory front, Voyageur formally commenced the FDA approval process in February 2026 via the 505(b)(2) pathway for barium contrast media. The FDA is expected to provide pending requirements in Q1 2026, with a review process anticipated to take 18 to 24 months, potentially enabling U.S. market entry as soon as mid-2027. The company plans to advance a generic iodine FDA license in the second half of 2026.
For iodine contrast media, Voyageur is independently advancing a prefeasibility study integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. This project targets 35 million doses per year, leveraging iodine-rich brine from U.S. oil and gas operations. The Bayer Iodine Project, governed by a Letter of Intent signed on December 20, 2024, focuses on completing a BFS for iodine feedstock production. Subject to successful BFS, Bayer may provide capital financing under an offtake-linked arrangement, with Voyageur operating the project. All intellectual property will remain exclusively owned by Voyageur.
Voyageur is engaging a global engineering company to complete the two BFS, positioning the company to become the only vertically integrated manufacturer of barium and iodine contrast media globally. The company is reviewing financial options to fund capital expenditures, targeting construction commencement in 2027. Management believes these efforts will provide affordable and secure supplies for healthcare authorities worldwide, reinforcing the 'From Earth to Bottle' value proposition.
